Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia
Candidate selection underscores Confo's ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus on metabolic and endocrine disorders Ghent, Belgium – December 18, 2025 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has selected CFTX-2034, an SSTR5 agonist, as its new antibody […]